您的当前位置:首页 > 行业数据 > Ivonescimab全球临床,OS未达到统计显著
图片属性
图片格式:PNG 图片大小:336KB 图片尺寸:1239*789
同报告图片
 / 4
Ivonescimab全球临床,OS未达到统计显著_第1页
PHxiZWdpbl9vZl9ib3h8Pnwg57uE5YirICAgICAgICAgICAgICAgfCBFdmVudHMsIG4gKCUpIHwgTWVkaWFuIChtbykgfCBIUiAoOTUlIENJKSAgIHwgUCBWYWx1ZSB8CnwtLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tfAp8IEl2b25lc2NpbWFiK2NoZW1vICB8IDEyMiAoNTUuNykgICAgfCAxNi44ICAgICAgICB8IDAuNzkgKDAuNjItMS4wMSkgfCAwLjA1NzAgIHwKfCBQbGFjZWJvK2NoZW1vICAgICAgfCAxNDAgKDYzLjkpICAgIHwgMTQuMCAgICAgICAgfCDigJQgICAgICAgICAgICAgfCDigJQgICAgICAgfAoK6LWE5paZ5p2l5rqQ77yaU3VtbWl0IOWumOe9keOAgeS4remCruivgeWIuOeglOeptuaJgDx8ZW5kX29mX2JveHw+
Ivonescimab全球临床,OS未达到统计显著_第2页
Ivonescimab全球临床,OS未达到统计显著_第3页
Ivonescimab全球临床,OS未达到统计显著_第4页
Ivonescimab全球临床,OS未达到统计显著_第5页
所属报告: 【中邮证券】君实生物(688180)-君实生物:PD-1/VEGF联用方案有望创新引领,国际化正扬帆起航-251023(28页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠